Value Microcaps Motherboard

[cleverrox]

VPHM. For instance, RPRX has two at least $500M+ a year Phase III drugs that are almost slam dunks to be approved by the FDA. One is Androxal a pill to fix secondary hypogonadism (low testosterone) and the other is for the untapped markets of uterine fibroids and endometriosis. The market cap of RPRX is $160M - less than a 3rd of VPHM's cash. They could at least buy stock in RPRX and try to gain a 25% stake. Or they could try to buy Androxal for $400M. That is a pile 'o cash just to fund a couple drugs in development. They have Vancocin revenue to do that with anyway.

With $6+ a share in cash versus a $7.70 share price the market has spoken. The market says we aren't sure about your existing revenue stream or your ability to put your cash to work.